Age and body weight adjusted warfarin initiation program for ischaemic stroke patients

European Journal of Neurology

Volumn 16, Issue 10, 2009, Pages 1100-1105

  Yoo, S H ^a   Nah, H W ^a   Jo, M W ^a   Kang, D W ^a   Kim, J S ^a   Koh, J Y ^a   Kwon, S U ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Initiation program; Ischaemic stroke; Maintenance dose; Warfarin

Indexed keywords

WARFARIN;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEALTH PROGRAM; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE;

AGE FACTORS; AGED; ANTICOAGULANTS; BODY MASS INDEX; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PATIENT SELECTION; SECONDARY PREVENTION; STROKE; THROMBOSIS; TREATMENT OUTCOME; WARFARIN;

EID: 70349260446     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02745.x     Document Type: Article

References (23)

1. Olsson SB. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003 362 : 1691 1698.
2. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 290 : 2685 2692.
3. Adams HP Jr., del Zoppo G, Alberts MJ, et al. Guidelines for early management of adults with ischemic stroke. Stroke 2007 38 : 1655 1711.
4. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007 38 : 423 430.
5. Hallevi H, Albright KC, Martin-Schild S, et al. Anticoagulation after cardioembolic stroke; to bridge or no to bridge? Arch Neurol 2008 65 : 1169 1173.
6. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001 119 : 22S 38S.
7. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 : 492 501.
8. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association\American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003 107 : 1692 1711. (Pubitemid 36397341)
9. Doufekias E, Segal AZ, Kizer JR. Cardiogenic and aortogenic brain embolism. J Am Coll Cardiol 2008 51 : 1049 1059.
10. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 126 : 204S 233S. (Pubitemid 39297955)
11. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomogram together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003 138 : 714 719.
12. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999 159 : 46 48.
13. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997 126 : 133 136.
14. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002 36 : 1512 1517.
15. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in the CYP2V9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 2007 8 : 1545 1550.
16. Cho HJ, Sohn KH, Park HM, et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 2007 8 : 329 337.
17. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005 39 : 1008 1012.
18. Dobrzanski S, Duncan SE, Harkiss A, Wardlaw A. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharm 1983 8 : 75 77.
19. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005 127 : 2049 2056.
20. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992 116 : 901 904.
21. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992 45 : 704 706.
22. Mungall D, White R. Aging and warfarin therapy. Ann Intern Med 1992 117 : 878 879.
23. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009 360 : 753 764.